Ligand Pharmaceuticals Down Over 12%, on Pace for Largest Percent Decrease Since February 2021 — Data Talk

Dow Jones Newswires

Ligand Pharmaceuticals

+0.46%

Ligand Pharmaceuticals Incorporated (LGND) is currently at $181.70, down $25.12 or 12.14%

Would be lowest close since Oct. 17, 2025, when it closed at $181.65
On pace for largest percent decrease since Feb. 11, 2021, when it fell 14.62%
Snaps a seven day winning streak
Down 3.9% month-to-date
Down 3.9% year-to-date
Down 13.19% from its all-time closing high of $209.29 on Nov. 10, 2025
Up 67.38% from 52 weeks ago (Jan. 14, 2025), when it closed at $108.55
Down 13.19% from its 52-week closing high of $209.29 on Nov. 10, 2025
Up 87.95% from its 52-week closing low of $96.67 on April 8, 2025
Traded as low as $178.43; lowest intraday level since Oct. 16, 2025, when it hit $178.34
Down 13.72% at today's intraday low; largest intraday percent decrease since Feb. 11, 2021, when it fell as much as 15.05%

All data as of 11:09:38 AM ET

Source: Dow Jones Market Data, FactSet

Risk Warnings and Disclaimers

You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.

Add to Favorites

Intel and Visa among market cap stock movers on Tuesday

Investing.com

Ligand Pharmaceuticals

+0.46%

Intuitive Surgical

-3.59%

Tuesday’s market has seen swings in various stocks based on news and other factors. Today, stocks like Intel and PerkinElmer are rallying, while stocks like Visa and Mastercard are falling. Below are highlights of some of the biggest stock movers, from mega-caps to small caps.

Mega-Cap Movers (Market Cap:$200B+)

Intel Corp (INTC) +6.67%
Adv Micro Device (AMD) +5.04%
Mastercard Cl A (MA); Compass Point upgrades MasterCard stock rating to Buy with $735 price target -5.17%
Visa Inc (V) -5.06%
JP Morgan Chase (JPM) -3.12%
Intuitive Surgical Inc (ISRG) -2.54%
Salesforce Com (CRM); Salesforce rolls out new AI-powered Slackbot for enterprise customers -4.29%
Morgan Stanley (MS); Morgan Stanley Capital Partners acquires majority stake in Olsson -1.77%

Large-Cap Stock Movers (Market Cap:$10B-$200B)

Regencell Bioscience Holdings (RGC) -18.27%
Perkinelmer (RVTY); Revvity expects to exceed Q4 guidance with 6% revenue growth +7.58%
Roblox Corp (RBLX) +6.94%
Moderna (MRNA) +6.56%
Cf Industries (CF) +4.67%
Penumbra Inc (PEN) -6.85%
Joby Aviation (JOBY) -7.82%
Chime Financial (CHYM) -6.57%
Super Micro Compu (SMCI) -7.45%
Pinduoduo (PDD) -5.86%

Mid-Cap Stock Movers (Market Cap:$2B-$10B)

Retrophin I (TVTX); Travere reports record FILSPARI sales of $103 million in Q4 2025 -30.21%
TTM Technologies (TTMI) +14.13%
TransMedics Group Inc (TMDX) +10.89%
BioScrip (OPCH); Option Care Health reports Q4 revenue of $1.46-1.47 billion +8.64%
Kennametal (KMT); Jefferies upgrades Kennametal stock rating to Buy on tungsten price spike +8.89%
Scorpio Tankers Inc (STNG); Scorpio Tankers reports $382.7 million net cash position +7.79%
Warby Parker (WRBY) +6.85%
Ligand Pharmaceuticals (LGND) -10.69%
iRhythm Technologies Inc (IRTC) -8.28%
Wildhorse Resource Development Corp (WRD) -8.99%

Small-Cap Stock Movers (Market Cap:$300M-$2B)

TryHard Holdings (THH) +59.78%
Rich Sparkle Holdings (ANPA) -29.31%
Kosmos Energy Ltd (KOS) +16.99%
Aspirational Consumer Lifestyle (UP) +14.04%
TECO Energy Inc-Exch (TE) +11.37%
Diginex Inc (DGNX) +11.36%
AMDL (AMDL) +10.76%
NovaBay Pharmaceuticals Inc (NBY) -17.47%
Esperion Th (ESPR) -15.21%
Qilian International Holding Group (BGM) -10.63%

For real-time, market-moving news, join Investing Pro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Risk Warnings and Disclaimers

Add to Favorites

Ligand Pharmaceuticals Is Maintained at Outperform by RBC Capital

Dow Jones Newswires

Ligand Pharmaceuticals

+0.46%

(14:36 GMT) Ligand Pharmaceuticals Price Target Raised to $235.00/Share From $234.00 by RBC Capital

Risk Warnings and Disclaimers

Add to Favorites

Ligand Pharmaceuticals Is Maintained at Buy by Stifel

Dow Jones Newswires

Ligand Pharmaceuticals

+0.46%

(13:15 GMT) Ligand Pharmaceuticals Price Target Raised to $230.00/Share From $220.00 by Stifel

Risk Warnings and Disclaimers

Add to Favorites

LGND: Five-year royalty growth outlook raised to 23% CAGR, anchored by high-performing assets

Quartr

Ligand Pharmaceuticals

+0.46%

Raised five-year royalty growth guidance to 23% CAGR, driven by commercial and development-stage assets, with strong financial performance and nearly $1B in deployable capital. Portfolio expansion, special situations, and new product launches like ZELSUVMI and Ohtuvayre underpin compounding value creation.

Based on Ligand Pharmaceuticals Incorporated [LGND] Investor Day 2025 Audio Transcript — Dec. 9 2025

Disclaimer

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Risk Warnings and Disclaimers

Add to Favorites

LGND: Strong revenue growth and portfolio expansion drive robust five-year outlook

Quartr

Ligand Pharmaceuticals

+0.46%

A diversified royalty aggregator leverages a lean, expert team to invest in over 100 biopharma assets, focusing on high-margin, low-risk cash flows. Recent financials show strong growth, with updated 2024 guidance and a robust five-year outlook driven by new product launches and portfolio expansion.

Based on Ligand Pharmaceuticals Incorporated [LGND] 17th Annual Southwest IDEAS Conference Audio Transcript — Nov. 20 2025

Disclaimer

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Risk Warnings and Disclaimers

Add to Favorites

LGND: Strong cash flow, portfolio growth, and minimal competition drive robust financial outlook

Quartr

Ligand Pharmaceuticals

+0.46%

A diversified royalty aggregator leverages a lean, expert team to invest in over 100 biopharma assets, generating strong cash flow and high margins. Recent product launches and outperforming assets have driven significant revenue and EPS growth, with a robust five-year outlook and minimal direct competition in its niche.

Based on Ligand Pharmaceuticals Incorporated [LGND] 17th Annual Southwest IDEAS Conference Audio Transcript — Nov. 20 2025

Disclaimer

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Risk Warnings and Disclaimers

Add to Favorites

Risk Disclosure

The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.

No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.

Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.

Recent Searches

Top Searches

Markets

News

Analysis

User

24/7

Economic Calendar

Education

Data

Ligand Pharmaceuticals Down Over 12%, on Pace for Largest Percent Decrease Since February 2021 — Data Talk

Intel and Visa among market cap stock movers on Tuesday

Ligand Pharmaceuticals Is Maintained at Outperform by RBC Capital

Ligand Pharmaceuticals Is Maintained at Buy by Stifel

LGND: Five-year royalty growth outlook raised to 23% CAGR, anchored by high-performing assets

LGND: Strong revenue growth and portfolio expansion drive robust five-year outlook

LGND: Strong cash flow, portfolio growth, and minimal competition drive robust financial outlook

Risk Disclosure